(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 167.58% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Cytokinetics's revenue in 2025 is $19,218,000.On average, 10 Wall Street analysts forecast CYTK's revenue for 2025 to be $8,221,374,850, with the lowest CYTK revenue forecast at $1,074,845,637, and the highest CYTK revenue forecast at $14,092,420,574. On average, 9 Wall Street analysts forecast CYTK's revenue for 2026 to be $18,646,541,538, with the lowest CYTK revenue forecast at $5,937,925,008, and the highest CYTK revenue forecast at $42,516,116,308.
In 2027, CYTK is forecast to generate $47,391,974,399 in revenue, with the lowest revenue forecast at $33,285,580,832 and the highest revenue forecast at $83,121,395,928.